Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Aurora M T, Poon"'
Autor:
David P, Nadebaum, Natasha, Krishnadas, Aurora M T, Poon, Victor, Kalff, Meir, Lichtenstein, Victor L, Villemagne, Gareth, Jones, Christopher C, Rowe
Publikováno v:
Internal Medicine Journal
Background Clinical diagnosis of Alzheimer disease (AD) is only 70% accurate. Reduced cerebral blood flow (CBF) and metabolism in parieto‐temporal and posterior cingulate cortex may assist diagnosis. While widely accepted that 18F‐fluoro‐2‐de
Autor:
Daisy Mak, Joanne McNamara, Michael Chao, M. Feigen, Michael Lim Joon, Aurora M T Poon, Patricia Jenkins, Andrew See, Daryl Lim Joon, A Mercuri, Morikatsu Wada, Vincent Khoo
Publikováno v:
Radiotherapy and Oncology. 97:205-211
Purpose To assess the correlation of 18F-FDG-PET (PET) response to pathological response after neoadjuvant chemoradiation (CRT) for locally advanced rectal cancer. Methods and materials Twenty patients with locally advanced rectal cancer were identif
Autor:
Richard J MacIsaac, Anna J Wood, Nayomi Perera, Elif I Ekinci, Leonid Churilov, George Jerums, David P. Thomas, Aurora M T Poon
Publikováno v:
Journal of diabetes and its complications. 30(1)
Aims To assess the performance of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation at baseline and longitudinally in people with type 2 diabetes. Methods Adults with type 2 diabetes attending Austin Health, Melbourne, with≥3
Autor:
Martin H, Cherk, Serene S, Foo, Aurora M T, Poon, Simon R, Knight, Carmel, Murone, Anthony T, Papenfuss, John I, Sachinidis, Timothy H C, Saunder, Graeme J, O'Keefe, Andrew M, Scott
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 47(12)
PET offers a noninvasive means to assess neoplasms, in view of its sensitivity and accuracy in staging tumors and potentially in monitoring treatment response. The aim of this study was to evaluate newly diagnosed non-small cell lung cancer (NSCLC) f
Publikováno v:
Clinical nuclear medicine. 29(4)
Positron emission tomography (PET) using F-18 fluorodeoxyglucose (FDG) is frequently used to diagnosis, stage, and assess response to therapy in patients with lung carcinoma. A 66-year-old man with a history of a left pleural effusion was referred to